How far are we from the “Treat all” era of antiviral therapy for chronic hepatitis B

Código QR

How far are we from the “Treat all” era of antiviral therapy for chronic hepatitis B

Guardado en:

Detalles Bibliográficos
Autor principal:	DING Yang
Formato:	article
Lenguaje:	ZH
Publicado:	Editorial Department of Journal of Clinical Hepatology 2021
Materias:	Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/5f4976458ba54d00a0b8f65e7440e753
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Antiviral therapy for chronic hepatitis B in the indeterminate phase is urgent
por: JIANG Jun
Publicado: (2021)

Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?
por: Lim TR
Publicado: (2014)

Patients with chronic hepatitis B virus infection in the indeterminate phase may benefit from antiviral therapy
por: XU Jinghang
Publicado: (2021)

Patients in the indeterminate phase of chronic hepatitis B virus infection should receive active antiviral therapy
por: WANG Jingyue
Publicado: (2021)

Patients in the indeterminate phase of chronic hepatitis B virus infection should be treated
por: JIANG Yingying
Publicado: (2021)

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
por: Kamal SM
Publicado: (2014)

Novel drugs in the management of difficult-to-treat hepatitis C genotypes
por: Cartwright EJ, et al.
Publicado: (2013)

Is it time we split bowel preparation for all colonoscopies? Outcomes from a national survey of bowel preparation practice in the UK
por: Thomas Archer, et al.
Publicado: (2021)

Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives
por: Degasperi E, et al.
Publicado: (2014)

Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis
por: Suad Abdeen, et al.
Publicado: (2011)

Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
por: Ismail MH, et al.
Publicado: (2011)

Interferon-free combination therapies for the treatment of hepatitis C: current insights
por: Holmes JA, et al.
Publicado: (2015)

Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
por: Janardhan SV, et al.
Publicado: (2015)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia MD, et al.
Publicado: (2011)

Epidemiology and treatment of autoimmune hepatitis
por: Francque S, et al.
Publicado: (2012)

Hepatitis C in Argentina: epidemiology and treatment
por: Gaite LA, et al.
Publicado: (2014)

Difficult bile duct cannulation: Do all roads lead to Rome?
por: Marianna Arvanitakis
Publicado: (2021)

Clinical features and prognosis of primary myelofibrosis with hepatic vascular disease and/or portal hypertension
por: WANG Jing
Publicado: (2021)

Endoscopic submucosal dissection: How to be more efficient?
por: Thomas Lambin, et al.
Publicado: (2021)

Transmission, diagnosis, and management of hepatitis E: an update
por: Mirazo S, et al.
Publicado: (2014)

Establishment and evaluation of a nomogram for predicting post-hepatectomy complications in two types of hepatic echinococcosis
por: GUO Bing
Publicado: (2021)

Update on entecavir in the management of severe forms of Hepatitis B
por: Sacco R
Publicado: (2012)

Ending hepatitis C in the United States: the role of screening
por: Coffin PO, et al.
Publicado: (2014)

Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis A vaccination program
por: Cervio G, et al.
Publicado: (2011)

The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
por: Danish FA, et al.
Publicado: (2013)

Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs
por: Roggeri DP, et al.
Publicado: (2015)

A high prevalence of extreme hyperferritinemia in acute hepatitis patients
por: Kazuhiro Kotoh, et al.
Publicado: (2009)

Risk factors for rebleeding after endoscopic selective variceal devascularization in patients with hepatitis B cirrhosis and acute variceal bleeding
por: MA Jiali
Publicado: (2021)

Hepatocyte-specific TM6SF2 knockout aggravates hepatic steatosis in mice with nonalcoholic fatty liver disease
por: ZHANG Jie
Publicado: (2021)

Hepatitis C infection in Egypt: prevalence, impact and management strategies [Corrigendum]
por: Gomaa A, et al.
Publicado: (2017)

Percutaneous hepatic radiofrequency for hepatocellular carcinoma: results and outcome of 46 patients
por: Bertr, et al.
Publicado: (2015)

Risk Prediction of Nosocomial and Posthospital Discharge Infections in Alcohol‐Associated Hepatitis
por: Daniel D. Penrice, et al.
Publicado: (2021)

A case of hepatic portal venous gas due to viral gastroenteritis
por: Mirmanesh M, et al.
Publicado: (2013)

Autonomic dysfunction in chronic liver disease
por: Frith J, et al.
Publicado: (2011)

Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine
por: Lau T, et al.
Publicado: (2013)

Association between hepatic fat and subclinical vascular disease burden in the general population
por: Susanne Rospleszcz, et al.
Publicado: (2021)

Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals
por: Elabd NS, et al.
Publicado: (2021)

New-onset ascites as a manifestation of virologic relapse in patients with hepatitis C cirrhosis
por: Chua DL, et al.
Publicado: (2014)

Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus
por: Bruno S, et al.
Publicado: (2011)

How deep is too deep? Gastrointestinal complication of COVID-19 deep nasal swab testing
por: Domenico A. Farina, et al.
Publicado: (2021)